

INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2024

Andy Hall, CEO & Dorette Neethling, CFO



OVERVIEW

ANDY HALL, CEO



PERFORMANCE

FINANCIAL



TURNOVER

-1%
R4.7b



TRADING PROFIT

-17%
R515m



HEPS

-9%
266 cents



DIVIDEND

115
cents

SEPA



2025

5.25%



2024

6.79%

MARKET SHARE



IQVIA DEC 2024 MAT

+4%

CONSUMER

REVENUE
R871m
+1%

TRADING PROFIT
R177m
-6%






OTC

REVENUE
R1 102m
-4%

TRADING PROFIT
R172m
+4%

IQVIA MAT
Dec 2024 (S1&S2)
+7%



PRESCRIPTION

REVENUE
R1 626m
-5%

TRADING PROFIT
R90m
-52%


IQVIA MAT
Dec 2024
+6%



HOSPITAL

REVENUE
R1 115m
+10%

TRADING PROFIT
R74m
-



- RENAL
- MEDICINE DELIVERY
- TRANSFUSION THERAPIES
- SPECIALISED THERAPIES



ESG JOURNEY

DURBAN DISTRIBUTION CENTRE



ELECTRIC VEHICLES



TRANSFORMATION

B-BBEE

Level

1




FINANCIAL PERFORMANCE

DORETTE NEETHLING, CFO



TURNOVER


-1%



■ PUBLIC ■ PRIVATE

R'MILLION

■ INCREASE ■ DECREASE ■ TOTAL




GROSS PROFIT

-5%

GROSS MARGIN


33%



■ EURO

■ US\$

IMPORTS - EXCHANGE RATES (FEC'S)



■ 2023 ■ 2024



INCOME STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 2024

TRADING PROFIT

-17%

	Dec 2024 R'm	Dec 2023 R'm	Change %
Revenue	4 714	4 740	(1%)
Cost of sales	(3 178)	(3 130)	(2%)
Gross profit	1 536	1 610	(5%)
Operating expenses	(1 021)	(992)	(3%)
Trading profit	515	618	(17%)



INCOME STATEMENT FOR THE SIX MONTHS ENDED 31 DECEMBER 2024

HEPS

-9%

	Dec 2024 R'm	Dec 2023 R'm	Change %
Trading profit	515	618	(17%)
Non-trading expenses	(28)	(32)	
Operating profit	487	586	(17%)
Equity accounted earnings	88	57	54%
Net finance cost	(59)	(39)	(51%)
Dividend income	1	1	
Profit before tax	517	605	(15%)
Tax	(127)	(161)	21%
Profit for the period	390	444	(12%)
HEPS (cents)	265.5	293.0	(9%)



BALANCE SHEET AS AT 31 DECEMBER 2024

DEPRECIATION

R97m

AMORTISATION

R5m

	Dec 2024 R'm	June 2024 R'm
Non-current assets		
Property, plant and equipment	1 444	1 449
Right-of-use assets	171	190
Intangible assets	1 226	1 114
Deferred tax assets	13	26
Other financial assets	16	18
Investment in joint ventures	753	672
	3 623	3 469



BALANCE SHEET AS AT 31 DECEMBER 2024

INVENTORY DAYS

149

TRADE RECEIVABLE
DAYS

63

TRADE PAYABLE
DAYS

62

	Dec 2024 R'm	June 2024 R'm
Current assets		
Inventories	2 732	2 541
Receivables and other current assets	2 292	2 224
Cash and cash equivalents	79	89
Tax receivable	17	32
	5 120	4 886



BALANCE SHEET AS AT 31 DECEMBER 2024

**INTEREST-BEARING
LIABILITIES
(LEASES)**

R262m

	Dec 2024 R'm	June 2024 R'm
Total equity		
Share capital	15	15
Share premium	267	267
Treasury share reserve	(799)	(799)
Non-distributable reserves	236	275
Retained income	5 825	5 655
Total shareholders' funds	5 544	5 413




SEGMENT
CONSUMER

TURNOVER

1%

TRADING PROFIT


-6%



- HEALTHCARE
- PERSONAL CARE
- HEMECARE

R'MILLION

■ INCREASE ■ DECREASE ■ TOTAL



SEGMENT


OTC

TURNOVER

-4%

TRADING PROFIT


+4%



- COUGH & COLD
- PAIN
- HEARTBURN & INDIGESTION
- ALLERGY
- OTHER

R'MILLION

■ INCREASE ■ DECREASE ■ TOTAL



SEGMENT


PRESCRIPTION

TURNOVER

-5%

TRADING PROFIT


-52%



- BRANDED
- ARV
- MNC
- GENERICS
- OTHER

R'MILLION

■ INCREASE ■ DECREASE ■ TOTAL




SEGMENT
HOSPITAL

TURNOVER

+10%

TRADING PROFIT


0%



■ PUBLIC ■ PRIVATE

R'MILLION

■ INCREASE ■ DECREASE ■ TOTAL





THANK YOU